Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer

Table 1 Patients characteristics n (%)

Characteristic	Folfiri 3 (n = 18)	Bevacizumab folfiri 3 (n = 99)	Aflibercept folfiri 3 (n = 36)	All (n = 153)	Comparison betweentreatments test P-value
Median age, yr (range)	62.5 (44-83)	64 (38-86)	66 (33-83)	64 (33-86)	0.33
Gender
Male	14 (67)	50 (51)	22 (61)	84 (55)	0.31
Female	6 (33)	49 (49)	14 (39)	69 (45)
Who performance status
0	2 (11)	12 (12)	6 (17)	20 (13)	0.47
1	11 (61)	75 (76)	25 (69)	111 (73)
2	5 (28)	12 (12)	5 (14)	22 (14)
Primary location
Right colon	3 (17)	33 (33)	8 (22)	44 (29)	0.51
Left colon	9 (50)	38 (39)	15 (42)	62 (41)
Rectum	6 (33)	28 (28)	13 (36)	47 (30)
Initial cancer status
Synchronous	14 (88)	26 (26)	20 (56)	46 (30)	0.09
Metachronous	4 (22)	73 (74)	16 (44)	107 (70)
Number of metastases
0 and 1	6 (33)	29 (29)	9 (25)	44 (29)	0.40
2	8 (40)	45 (46)	12 (33)	65 (42)
3 and more	4 (22)	25 (25)	15 (42)	44 (29)
Surgery of primary
No	7 (39)	38 (38)	14 (39)	59 (39)	1.00
Yes	11 (61)	61 (62)	22 (61)	94 (61)
Surgery of metastases
No	14 (78)	78 (79)	28 (88)	120 (81)	0.53
Yes	4 (22)	21 (21)	4 (12)	29 (19)
Unknown	-	-	4	4
Line of therapy
Second	5 (28)	17 (17)	4 (12)	26 (17)	0.52
Third	3 (17)	22 (22)	11 (31)	36 (24)
More	10 (55)	60 (61)	21 (57)	91 (59)
Irinotecan chemotherapy-naive
No	13 (72)	81 (82)	31 (86)	125 (82)	0.46
Yes	5 (28)	18 (18)	5 (14)	28 (18)
RAS/BRAF mutation status
Not mutated	11 (69)	36 (44)	16 (44)	63 (47)	0.18
At least one mutated	5 (31)	46 (56)	20 (56)	71 (53)
Unknown	2	17	-	19
Best overall response
PD	3 (17)	8 (8)	0 (0)	11 (7)	0.20
SD	1 (5)	9 (9)	7 (19)	17 (11)
PR	11 (61)	48 (48.5)	15 (42)	74 (48)
CR	0 (0)	3 (3)	1 (3)	4 (3)
NE	3 (17)	31 (31.5)	13 (36)	47 (31)
Median PFS, mo (95%CI)	3.0 (0.8-6.9)	3.7 (3.0-5.3)	4.7 (3.3-12.8)	3.9 (3.2-4.9)	-
Median OS, mo (95%CI)	5.6 (4.0-20.2)	8.5 (6.4-10.7)	13.7 (7.9-18.7)	9.4 (6.6-12.0)	-

PD: Progression disease; SD: Stable disease; PR: Partial response; CR: Complete response; NE: None evaluable; PFS: Progression free survival; OS: Overall survival.